Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Colston · SciRah

Researcher profile · Semantic Scholar

E. Colston

Share profile

E. Colston — researcher profile on SciRah

h-index: 13
Works: 36
Citations: 1,313

Most-cited papers

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
A. Armstrong, M. Gooderham, R. Warren, K. Papp +12 more
2022Journal of American Academy of Dermatology317 citations Open access
Semantic Scholar
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial.
B. Strober, D. Thaçi, H. Sofen, L. Kircik +12 more
2022Journal of American Academy of Dermatology224 citations Open access
Semantic Scholar
Immune checkpoint inhibition in sepsis: a Phase 1b randomized, placebo-controlled, single ascending dose study of anti-PD-L1 (BMS-936559)
R. Hotchkiss, E. Colston, Sachin P. Yende, D. Angus +11 more
2019Critical Care Medicine207 citations Open access
Semantic Scholar
Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab
R. Hotchkiss, E. Colston, Sachin P. Yende, E. Crouser +16 more
2019Intensive Care Medicine198 citations Open access
Semantic Scholar
Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition
E. Colston, V. Racaniello
1995Journal of Virology79 citations Open access
Semantic Scholar
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2)
B. Strober, A. Blauvelt, Richard B. Warren, K. Papp +11 more
2024Journal of the European Academy of Dermatology and Venereology42 citations Open access
Semantic Scholar
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open‐label, phase 3 trial
S. Imafuku, Yukari Okubo, Y. Tada, M. Ohtsuki +5 more
2024Journal of dermatology (Print)33 citations Open access
Semantic Scholar
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies.
Kap-Sun Yeung, Brett R. Beno, Kyle Parcella, J. A. Bender +33 more
2017Journal of Medicinal Chemistry31 citations Open access
Semantic Scholar
The Effect of Hepatic Impairment on the Pharmacokinetics of Asunaprevir, an HCV NS3 Protease Inhibitor
T. Eley, B. He, I. Chang, E. Colston +6 more
2015Antiviral Therapy31 citations
Semantic Scholar
Integration of the BALB/c ecotropic provirus into the colony-stimulating factor-1 growth factor locus in a myc retrovirus-induced murine monocyte tumor
William R. Baumbach, E. Colston, Michael D. Cole
1988Journal of Virology29 citations Open access
Semantic Scholar
POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
A. Armstrong, M. Gooderham, R. Warren, K. Papp +7 more
202127 citations Open access
Semantic Scholar
An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients
E. Colston, D. Grasela, D. Gardiner, R. P. Bucy +3 more
2018PLoS ONE24 citations Open access
Semantic Scholar
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: a subset analysis of two phase 3 randomized trials in plaque psoriasis.
A. Blauvelt, Phoebe Rich, H. Sofen, B. Strober +10 more
2023Journal of American Academy of Dermatology19 citations Open access
Semantic Scholar
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
B. Strober, D. Thaçi, H. Sofen, L. Kircik +12 more
2023Immunotherapy10 citations Open access
Semantic Scholar
AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
R. Warren, A. Armstrong, M. Gooderham, B. Strober +12 more
2022Annals of the Rheumatic Diseases9 citations Open access
Semantic Scholar
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
D. Thaçi, K. Gordon, M. Gooderham, B. Strober +6 more
2021SKIN The Journal of Cutaneous Medicine6 citations Open access
Semantic Scholar
Higher Sustained Virologic Response (SVR-12) Achiev- able in Liver Transplant (LT) Recipients with Hepatitis C (HCV) Treated with Protease Inhibitor (PI) Triple Therapy (TT)
T. Garimella, B. He, W. Luo, E. Colston +17 more
20135 citations
Semantic Scholar
Deucravacitinib long-term efficacy with continuous treatment in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program
M. Lebwohl, R. Warren, H. Sofen, S. Imafuku +12 more
2023SKIN The Journal of Cutaneous Medicine4 citations Open access
Semantic Scholar
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials
R. Warren, A. Armstrong, M. Gooderham, B. Strober +12 more
2022SKIN The Journal of Cutaneous Medicine4 citations Open access
Semantic Scholar
822Effect of Steady State Daclatasvir Plus Asunaprevir on the Single Dose Pharmacokinetics of the P-glycoprotein Substrate Digoxin in Healthy Adult Subjects
T. Garimella, R. Adamczyk, M. Stonier, H. Kandoussi +4 more
2014Open Forum Infectious Diseases4 citations Open access
Semantic Scholar
Mechanisms of Hyperbilirubinemia During Peginterferon Lambda-1a Therapy for Chronic Hepatitis C Infection: A Retrospective Investigation
R. Zwirtes, Premkumar Narasimhan, Megan Wind-Rotolo, Dong Xu +4 more
2016Journal of Interferon and Cytokine Research3 citations
Semantic Scholar
The pharmacokinetics of peginterferon lambda-1a following single dose administration to subjects with impaired renal function.
M. Hruska, R. Adamczyk, E. Colston, M. Hesney +3 more
2015British Journal of Clinical Pharmacology3 citations Open access
Semantic Scholar
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary.
A. Armstrong, M. Gooderham, R. Warren, K. Papp +12 more
2023Immunotherapy2 citations Open access
Semantic Scholar
43872 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Scalp, Nail, and Palmoplantar Psoriasis in Japanese Patients With Plaque Psoriasis: Subset Analysis of the Phase 3 POETYK PSO-4 Trial
S. Imafuku, Yukari Okubo, Y. Tada, M. Ohtsuki +5 more
2023Journal of American Academy of Dermatology1 citations
Semantic Scholar
34658 Deucravacitinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe plaque psoriasis who had inadequate responses to apremilast at week 24 in the phase 3 POETYK PSO-1 and PSO-2 trials
A. Armstrong, R. Warren, H. Sofen, L. Spelman +7 more
2022Journal of American Academy of Dermatology1 citations
Semantic Scholar
823Evaluation of Drug-Drug Interaction between Asunaprevir and Methadone or Buprenorphine/Naloxone
T. Garimella, T. Eley, B. He, W. Luo +6 more
2014Open Forum Infectious Diseases1 citations Open access
Semantic Scholar
43851 Deucravacitinib Long-term Efficacy With Continuous Treatment in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO-1 and POETYK PSO-LTE Trials
M. Lebwohl, R. Warren, L. Kircik, E. Colston +7 more
2023Journal of American Academy of Dermatology0 citations
Semantic Scholar
43110 Deucravacitinib, a Selective Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Plaque Psoriasis: PASI Body Region and Component Scores in a Phase 3 Trial
Y. Tada, S. Imafuku, Yukari Okubo, M. Ohtsuki +6 more
2023Journal of American Academy of Dermatology0 citations
Semantic Scholar
39861 Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Psoriasis: Absolute PASI Outcomes in a Phase 3 Trial
Yukari Okubo, S. Imafuku, Y. Tada, M. Ohtsuki +6 more
2023Journal of American Academy of Dermatology0 citations
Semantic Scholar
43879 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 2-year Efficacy by Prior Biologic Treatment in the Phase 3 POETYK PSO Program
Richard B. Warren, April W. Armstrong, S. Imafuku, Carle Paul +6 more
2023Journal of American Academy of Dermatology0 citations
Semantic Scholar
Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
M. Gooderham, L. Spelman, S. Imafuku, M. Romanelli +6 more
2023SKIN The Journal of Cutaneous Medicine0 citations Open access
Semantic Scholar
43827 Deucravacitinib Long-term Efficacy in Patients Originally Randomized to Placebo: 2-Year Results From the POETYK PSO Program
M. Lebwohl, R. Warren, S. Imafuku, J. Bagel +7 more
2023Journal of American Academy of Dermatology0 citations
Semantic Scholar
43887 Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Efficacy by Baseline Demographic and Disease Characteristics in the Phase 3 POETYK PSO-1 and PSO-2 Trials
M. Gooderham, L. Spelman, S. Imafuku, Marco Romanelli +6 more
2023Journal of American Academy of Dermatology0 citations
Semantic Scholar
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
N. Korman, K. Papp, J. Bagel, P. Foley +6 more
2021SKIN The Journal of Cutaneous Medicine0 citations Open access
Semantic Scholar
1504: IMMUNE CHECKPOINT INHIBITORS IN SEPSIS
Richard Hotchkiss, E. Colston, Sachin P. Yende, Derek C. Angus +15 more
20180 citations
Semantic Scholar
P1140 PEGINTERFERON LAMBDA-1a PHARMACOKINETICS IN SUBJECTS WITH IMPAIRED RENAL FUNCTION
R. Adamczyk, E. Colston, M. Hesney, M. Stonier +3 more
20140 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Thaçi×14
Invite
D. Thaçi — researcher profile on SciRah
S. Imafuku×12
Invite
S. Imafuku — researcher profile on SciRah
B. Strober×11
Invite
B. Strober — researcher profile on SciRah
A. Blauvelt×11
Invite
A. Blauvelt — researcher profile on SciRah

×10

Invite

J. Throup — researcher profile on SciRah

Subhashish Banerjee×10

Invite

Subhashish Banerjee — researcher profile on SciRah

Subhashis Banerjee×9

Invite

Subhashis Banerjee — researcher profile on SciRah

M. Gooderham×8

Invite

M. Gooderham — researcher profile on SciRah

Invite

R. Warren — researcher profile on SciRah

Invite

K. Papp — researcher profile on SciRah

Invite

H. Sofen — researcher profile on SciRah

Invite

A. Napoli — researcher profile on SciRah